Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)
Go back to Priovant Expands Brepocitinib Development Program with New Phase 2b/3 Trial in Lichen Planopilaris (LPP)| (NASDAQ: ROIV) | Delayed: 32.21 +0.96 (3.07%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $31.25 | 52 Week High | $ | |||
| Open | $31.05 | 52 Week Low | $ | |||
| Day High | $32.80 | P/E | N/A | |||
| Day Low | $30.70 | EPS | $ | |||
| Volume | 7,365,040 | |||||
